Business context and reporting period
Filing identity differs from the request metadata: the supplied 10-Q is for Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc. It covers the quarter and nine months ended September 30, 2018. Rexahn was a clinical-stage oncology biopharmaceutical company with no product revenue.
Financial results and liquidity
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $2.89m | $2.64m | $10.38m | $7.45m |
| General and administrative expense | $1.80m | $1.57m | $5.19m | $5.00m |
| Net loss | $5.34m | $1.04m | $11.25m | $21.70m |
| Basic and diluted loss per share | $0.17 | $0.04 | $0.35 | $0.83 |
| Cash used in operations | Not stated for quarter | Not stated for quarter | $14.22m | $11.72m |
At September 30, cash and cash equivalents were $4.59m and marketable securities were $7.97m, totaling about $12.57m; working capital was approximately $10.4m. Total liabilities were $7.46m, including $4.10m of warrant liabilities. No conventional borrowings are identified in the supplied filing text. Gross margin is not applicable because the company reported no revenue.
Total assets were $13.87m, down from $28.29m at December 31, 2017. Cash and cash equivalents declined from $8.90m; marketable securities fell from $17.93m. Nine-month investing cash inflow of $9.91m largely reflected securities redemptions. There was no financing cash inflow in the first nine months of 2018.
Material changes and unusual items
Nine-month R&D expense rose 39.3%, mainly from higher clinical-trial and drug-manufacturing costs; G&A increased 3.7%. R&D spending on RX-3117 and RX-5902 increased as their trials advanced. Q3 net loss widened year over year, while the nine-month net loss narrowed substantially. Comparisons were materially affected by noncash warrant fair-value changes: a $0.71m loss in Q3 2018 versus a $3.12m gain in Q3 2017, and a $3.75m gain for nine months 2018 versus a $9.05m loss for nine months 2017. The filing also recorded $0.37m of other income from terminating the Rexgene agreement.
On October 19, 2018, Rexahn completed a registered direct offering of shares and warrants for approximately $7.5m gross proceeds. The company said cash, marketable securities, and offering proceeds were expected to fund current operations through Q3 2019, but additional capital would be required thereafter. Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements.
Outlook, risks, and contingencies
Management expected RX-3117 expenses to remain roughly flat for the rest of 2018 versus Q3 and RX-5902 expenses to decrease slightly, primarily as manufacturing campaigns concluded. RX-0201 expenses were expected to remain flat while the internally funded metastatic renal-cell-cancer trial was wound down. These are management expectations, not financial guidance.
The company was conducting Phase 2 studies of RX-3117 and RX-5902 and had entered a Merck collaboration for a Phase 2 trial combining RX-5902 with Keytruda in metastatic triple-negative breast cancer; Merck was to supply Keytruda at no cost, while Rexahn sponsored the trial. Risks include clinical and regulatory uncertainty, reliance on outside research organizations and manufacturers, the need for additional capital, and the possibility that financing may not be available on acceptable terms. Estimated remaining costs under vendor research and development agreements were approximately $6.98m; the filing states these agreements may be terminated on notice. A potential $1.0m KRICT milestone had not been triggered. Under the terminated Rexgene arrangement, future RX-0201 Asia sales and licensing receipts may carry royalty or revenue-sharing obligations, capped at $5.0m.
Important facts to verify
- Confirm the issuer: this source is Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Verify the October 2018 offering’s net proceeds, associated fees, and potential dilution from the accompanying warrants.
- Assess whether the stated runway through Q3 2019 remains credible given operating cash use of $14.22m in the first nine months of 2018 and the going-concern warning.
- Track clinical-trial progress, collaboration terms, and the timing and cost of further development and manufacturing.
- Review warrant-liability valuation assumptions and potential effects of future stock-price and volatility changes on reported earnings.